What started with diabetes and weight loss is now extending to several potential uses, and the FDA is welcoming these new applications for approval
However, for women with obesity, type 2 diabetes or significant metabolic dysfunction, prescription medications may be appropriate and more effective
Similarly, the SELECT cardiovascular outcome trial, which followed over 17,000 patients with obesity but without diabetes for more than three years, found no significant elevation in cancer rates among semaglutide users
Paid subscribers have also received our view on being long smaller, clinical stage names like Gubra (GUBRA DC), Zealand Pharma (ZEAL DC) and Amgen (AMGN US)
One Doctor, Not a Call Center You work directly with Dr